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Determination of complication rate of PICC lines in Oncological Patients
Ghulam Haider, Shiyam Kumar, Basit Salam, Nehal Masood, Asim Jamal, Yasmeen Abdul Rasheed
Section Hematology, Oncology Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: To determine the complication rate of (PICCs) peripherally inserted central catheters in cancer
patients with a 1 year prospective cohort study.
Methods: All PICCs inserted in adult cancer patients in Radiology Department of The Aga Khan University Hospital
were followed prospectively till removed or patient expired and pattern of complications noted.
Results: One hundred and fourty six PICCs were inserted over a period of 1 year and followed for a total of 3329
catheter-days; median placement, 14 days: range 3-218 days. Of these 67 (32.8%) PICCs were complicated and
removed earlier, for a rate of 14.4/1000 PICC-days. Patients with haematologic malignancies were more likely
to have complications as compared to those with solid tissue malignancies.
Conclusions: Despite a significant complication rate, PICCs are a relatively safe and cost effective method of
establishing central venous access (JPMA 59:663; 2009).
Introduction
Peripherally inserted central catheters (PICCs)
represent a vascular access device (VAD) that can be
considered to have an intermediate role in central venous
access. Peripherally inserted central catheters can be made
of either silicon rubber or polyurethane, the former being
associated with a lower risk of thrombosis.1
Effective and reliable venous access is one of the
cornerstones of modern medical therapy. With advancing
age and increasing Co morbidities in our modern society,
effective and reliable venous access can sometimes be very
difficult to establish. PICCs provide reliable and safe
intravenous access in a variety of indications.2
PICC lines are frequently used in oncology patients
to deliver chemotherapy as well as other intravenous
medications, fluids and total parenteral nutrition.3
Peripherally inserted central catheters offer certain
advantages over other forms of long-term VAD.4
In particular, the use of PICC has provided a
relatively simple,safe,easy,rapid and maintenance free
means of accessing a central vein for the purposes of
chemotherapy or other intravenous fluids.5
Despite the widespread use of PICCs, few
prospective studies evaluating their safety have been
performed, and even fewer have focused on patients with
cancer. Overall, the complication rate in cancer patients
appears to be higher than in other patients, 
Therefore, we conducted this prospective study to
determine the complication rate of PICCs in cancer patients
attending our hospital.
Patients and Methods
The Aga Khan University Hospital (AKUH) is a
650 bed tertiary care center in Karachi, Pakistan. Medical
Oncology Section is comprised of a 50 bedded inpatient
unit with a four bedded BMT unit and a 30 bedded Day
care chemotherapy unit. All the cancer inpatients who
deemed to have difficult venous access or requiring a
central venous access for multitude of indications,
particularly chemotherapy after recommendation by
primary care physician were referred to the department of
Radiology for PICC insertion. We have a dedicated
Interventional Radiology Team who inserts 4 Fr single
lumen non-valved PICC under strict anti-septic
conditions, and fluoroscopic guidance in Angiography
suit. The PICC is inserted in any of the major vein of the
upper extremities, more frequently in basilic vein and
secured by stat-lock adhesive dressing. The polyurethane
catheter is used because of its wide luminal diameter and
easy blood products transfusion. It is recommended to be
kept in place for 6-8 weeks duration by the manufacturer.
It can be used for a longer period of time if no
complication develops.
We prospectively identified and followed all patients
who had a PICC successfully Inserted during a 1 year
period, from March 1, 2007, to February 29, 2008, until
they were removed or  patient expired The project was
approved by the AKUH Institutional Ethical Review
Committee.
PICC maintenance:
PICCs are used for all types of infusions and
phlebotomy. The primary care inpatient nurse is
responsible for catheter care, changes both dressing and IV
tubing three times weekly and as needed, and performs the
weekly saline flush. The IV insertion team is responsible
for repair of torn catheters and unblocking of catheters. For
caring of PICC at home after discharge, either home health
care team or patients attendants were given detailed
instructions regarding care of catheter. Patients were called
at home daily on phone regarding any evidence of
complication and advised to come to the ward if any
complication developed.
A single reason was determined for any PICC
removed prematurely. Reasons included catheter-related
bloodstream infection (CR-BSI), phlebitis, thrombosis,
catheter occlusion, leakage or broken catheter, or accidental
removal. The decision to remove a PICC line was made by
the patient's primary physician. The data regarding PICC
were entered into an already formed proforma and filled by
the principal investigator.
Twenty-six patients had more than one PICC placed
during the study period. For the analysis, each PICC
placement was counted as a new event. Therefore, all
presented calculations, including the demographic
description of the patient group, used PICC placements
rather than individual patients as the unit for counting. For
data analysis SPSS version 15 was used.
Results
A total of 166 PICCs were inserted into 128 patients
during the 9 months study period. One Patient had six
PICCs inserted, five patients had four PICCs, six patients
had three PICCs and 12 patients had two PICCs inserted.
One patient had two PICCs, one on each arm at the same
time. Twenty patients with their 20 PICCs were lost to
follow up and were excluded from the Analysis. For the
remaining 122 patients and their 146 PICCs, the data was
available for analysis. The demographic profile of 146
patients and the primary indications for PICC placement are
listed in Table-1.
Overall, the patient population included 93 (63.3%)
men and 53 (36.7) women, with a mean age 43.1±16.7 years
(range, -> 16-82 years). Seventy four patients (50.68%) had
a solid tumour, and 72 (49.32%) had haematological
malignancy. Among the solid tumours, the most common
were gastrointestinal malignancies, (50%).Acute myeloid
leukaemia was the most common (66.3) among the
haematological malignancies. The basilic vein was used
most frequently, 119 (81.6%) for PICC placement. All the
PICCs were secured by the stat-lok device.
Sixty seven patients (46%) were discharged from
Hospital with a PICC still in place. Follow-up for these
patients was arranged with home health care team, on
phone and frequent follow ups in clinic. The remaining 79
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patients (54%) remained hospitalized for the entire
duration of PICC use.
The 146 PICCs were in place for a total of 3329
catheter-days (median time, 14 days; range, 2 to 218
days; mean, 23.8 ± 29.8 days). The most common
indication for PICC were chemotherapy (60.3%). The
most frequently used chemotherapy regimen was
induction chemotherapy for Acute Myeloid Leukaemia
followed by FOLFOX for coloxectal carcinoma.
Majority of patients (54%) preferred PICC in sections,
remaining were not clear about, which line to be
preferred and decision were left on primary physicians
care discretion.
Demographic and disease characteristics of the 146
patients receiving a PICC are given in Table-1 and reasons
of PICC removal are listed in Table-2. PICCs in sixty seven
patients removed due to complications.
Ninety-eight (67.1%) PICCs were removed at
completion of therapy without any evidence of
complication.
Forty-eight (32.8%) of 146 PICCs were removed
because of complication, rate of 14.4 per 1,000 catheter-
days.PICCs of patients with Haematologic malignancies
were more likely to be complicated (p=<0.05).
Infections were the most common complication
reported, but culture proven to be positive in 11 patients
(29.7%), of them 7 (4.9%) were blood culture positive, 4
(2.8%) catheter tip positive and in 4 (2.1%) cases both blood
and catheter tip cultures were positive.
Blood culture yielded E.coli in 4 cases and one of
each of Staphylococcus Aureus, Staphylococcus
epidermidis and Enterococcus.Catheter tip grew
Staphylococcus Epidermidis in two cases and
Staphylococcus Aureus and Enterococcus each in one case.
Discussion
PICCs are now becoming more popular than other
Central Venous Catheters (CVCs), because of ease of
insertion and removal, cost-effectiveness and low procedure
related complications. PICCs have made administration of
chemotherapy much safe and reliable. However its
complications in cancer patients have not been much
studied, therefore we studied prospectively its complication
rate in cancer patients.
We found a complication rate of 32.8% and
14.4/1000 PICC-days, which is similar to that found by
Walshe et al, 32.8%, 10.9/1000 PICC-days, the largest
prospective study in 351 cancer patients.9 However the
pattern of complication was different in the two studies. The
complication rate was more in the retrospective study of K.
Cheong et al;7 in comparison to our study, in which the
overall complication rate was 40.7%, but infective
complications were less, which is 25.9% at a rate of 8/1000
PICC-days.
The comparison of our result with other studies is
given in Table-3. 
The most common complication in our study was
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Table-1: Characteristics of the patients Receiving a PICC (n=146).
Characteristics No. of patient % 
Age by quartile (years)
16-40 63 43.2
41-50 30 20.5
51-60 32 22.1
61-70 16 11.1
>70 05 3.1
Mean age years 43.1 ± 16.7
Sex
Male 93 63.3
Female 53 36.7
Underlying cancer
Solid tumors (n-74) 74 50.8
Gastric carcinoma 14 9.5
Lymphomas 14 9.5
Colorectal carcinoma 13 8.9
Sarcomas 07 4.8
Pancreatico-biliary 07 4.8
Esophageal ca 05 3.4
Lung cancer 03 2.0
Others 11 7.5
Hematologic Malignancies (n-72) 72 49.3
AML 48 66.3
ALL 15 20.8
Myeloma 6 8.3
CLL 3 4.1
Primary indication for PICC
Chemotherapy 88 60.6
TPN 29 24.0
IV access 23 12.0
K-Replacement 13 8.0
Site of PICC
Right Basilic vein 103 70.5
Left Basilic vein 16 11.0
Right cephalic vein 9 6.1
Left cephalic vein 3 2.1
Right brachial vein 12 8.2
Left brachial 3 2.1
Table-2: Reasons of PICC removal and outcome of all PICCs (n-146).
Condition No. of patients % Rate per 1000 catheter-
days
No complication 98 67.1 -
Complications 48 32.8 14.4
Infections 37 25.3 11.1
Systemic 27 18.4 8.1
Phlebitis 10 6.8 3.0
Blockage 6 4.1 1.8
Accidental removal 3 2.0 0.9
Leakage 1 0.7 0.3
Thrombosis 1 0.7 0.3
infection which resulted in PICC removal in 37 (25.3%),
at a rate of 11.1/1000 PICC-days. This is in contrast to
the result of Walshe et al;9 in which infection rate was
7.4% (2.5/1000 PICC-days). In the study by Safdar et al.6
A prospective study of 251 ICU patients found a
complication rate similar to other Subcutaneously
implanted CVCs as PICC related infection rate was 2.4%
a rate of 2.1/1000 catheter-days. The complication rate
also seems to depend on the infusate being given through
the PICC. PICCs when being used for only IV
antibiotics, the complication rate have been found to be
low as compared those where multiple infusates are
being given through the PICC for example
chemotherapy, blood products and electrolyte infusion
and antibiotics.
The above findings can be further confirmed by the
study conducted by Chu et al;2 (Australasian Radiology) in
which 44 PICCs were placed in 44 patients for only IV
antibiotics and a complication rate of 5.5/1000 PICC days
was found with infective complication rate of 0.8/1000
PICC days.
Our recent PICC complication rate compares
favourably with published series in the oncology setting
Walshe et al;9 Cheong et al,7 but comparison of
complication rates across various institutions can also be
difficult due to the varying definition of PICC
complications. Theoretically patients who have PICCs in
situ for only short periods of time, may be at lower risk
of developing complications, resulting in apparently
lower complication rate, but expressing PICC
complication rate as complication per 1000 PICC-days
may compensate for this.
Our infective complication rates were more, but
thrombotic complications were less as compared to Walshe
et al,9 Cheong et al7 and Chu et al.2 This could be due to the
fact that large number of our patients with haematological
malignancies were neutropenic at the time of PICC
insertion and at least for sometime thereafter, also we used
our PICCs for all kinds of infusate, chemotherapy, blood
products transfusion, electrolytes infusion and antibiotics,
which could be the reason for more complications. This is
the first study of its kind in Pakistan as only two to three
Hospitals in our country have facility and expertise of PICC
line placement.
Conclusion
PICCs provide safe and cost effective central
venous access for all kinds of indications. Peripherally
inserted central catheter complication rates can be
minimized if used and maintained appropriately. This
includes PICC insertion under strict sterile conditions,
patient family and staff education with formal aftercare
guidelines, strict infection control and regular PICC
maintenance and surveillance, making them a safe and
acceptable venous access alternative for cancer patients.
However a prospective study is needed to compare safety,
efficacy and quality of life of patients with PICC and
implanted ports.
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